Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Urbahns

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
ACS Infectious Diseases|October 15, 2020
Targeted Covalent Inhibitors for the Treatment of Malaria?Shashank Kulkarni, Klaus Urbahns, Thomas Spangenberg
Angewandte Chemie (International Ed. in English)|October 4, 2017
Small Molecules Drive Big Improvements in Immuno-Oncology TherapiesBayard R Huck, Lisa Kötzner, Klaus Urbahns
Progress in Medicinal Chemistry|May 5, 2020
Small molecules-Giant leaps for immuno-oncologyLisa Kötzner, Bayard Huck, Sakshi Garg, et al.
Nature Reviews. Drug Discovery|August 18, 2022
The expanding role for small molecules in immuno-oncologyRienk Offringa, Lisa Kötzner, Bayard Huck, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2003
4-Phenyl-4H-pyrans as IK(Ca) channel blockersKlaus Urbahns, Ervin Horváth, Johannes Peter Stasch, et al.
Journal of Medicinal Chemistry|February 9, 2008
Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationshipsIgor Shamovsky, Stephen Connolly, Laurent David, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2010
Glycine amides as PPARalpha agonistsKlaus Urbahns, Michael Woltering, Susanne Nikolic, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
IKCa-channel blockers. Part 2: discovery of cyclohexadienesKlaus Urbahns, Siegfried Goldmann, Jochen Krüger, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 2002
Biphenyls as potent vitronectin receptor antagonistsKlaus Urbahns, Michael Härter, Markus Albers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 22, 2020
Crystalline Sponges as a Sensitive and Fast Method for Metabolite Identification: Application to Gemfibrozil and its Phase I and II MetabolitesLara Rosenberger, Carolina von Essen, Anupam Khutia, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
ACS Infectious Diseases|October 15, 2020
Targeted Covalent Inhibitors for the Treatment of Malaria?Shashank Kulkarni, Klaus Urbahns, Thomas Spangenberg
Angewandte Chemie (International Ed. in English)|October 4, 2017
Small Molecules Drive Big Improvements in Immuno-Oncology TherapiesBayard R Huck, Lisa Kötzner, Klaus Urbahns
Progress in Medicinal Chemistry|May 5, 2020
Small molecules-Giant leaps for immuno-oncologyLisa Kötzner, Bayard Huck, Sakshi Garg, et al.
Nature Reviews. Drug Discovery|August 18, 2022
The expanding role for small molecules in immuno-oncologyRienk Offringa, Lisa Kötzner, Bayard Huck, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2003
4-Phenyl-4H-pyrans as IK(Ca) channel blockersKlaus Urbahns, Ervin Horváth, Johannes Peter Stasch, et al.
Journal of Medicinal Chemistry|February 9, 2008
Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationshipsIgor Shamovsky, Stephen Connolly, Laurent David, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2010
Glycine amides as PPARalpha agonistsKlaus Urbahns, Michael Woltering, Susanne Nikolic, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
IKCa-channel blockers. Part 2: discovery of cyclohexadienesKlaus Urbahns, Siegfried Goldmann, Jochen Krüger, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 2002
Biphenyls as potent vitronectin receptor antagonistsKlaus Urbahns, Michael Härter, Markus Albers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 22, 2020
Crystalline Sponges as a Sensitive and Fast Method for Metabolite Identification: Application to Gemfibrozil and its Phase I and II MetabolitesLara Rosenberger, Carolina von Essen, Anupam Khutia, et al.
Pageof 3